Effectiveness of HeberFERON® in the treatment of basal cell carcinoma of the back of the nose

Abstract

Introduction: basal cell carcinoma is the most common cause of neoplasms, without distinction between racial groups, ethnic groups or ages.

Objective: to evaluate the effectiveness of HeberFERON® for the treatment of basal cell carcinoma of the back of the nose.

Methods: a pre-experimental study of the before and after type was carried out at the Ciego de Ávila Provincial General Teaching Hospital, in the period July 2017 to April 2019. It worked with the 32 adults who met the inclusion criteria. Two treatment schemes were applied with different doses and ways of administration. Chi-square, Mann-Whitney's U, and Cochran's Q tests were used. Ethical principles were met.

Results: the general mean age was 70 years (DT =16,0) with a predominance of males (59,40 %), urban origin (56,25 %), skin phenotype II (53,10 %), the clinical form and nodular dermatological pattern, and erythema as an adverse event. The complete clinical response was observed in all histological forms and patterns, with a predominance of the nodular. The frequency of applications was associated with the complete clinical response. Telangiectasia was the most commonly observed dermoscopic finding (100 %). Only one patient presented partial persistence of the injury to the second year, unrelated to the number or type of injury.

Conclusions: the therapeutic effectiveness of HeberFERON® was demonstrated in patients with basal cell carcinoma of the back of the nose. In all clinical forms and histological patterns studied, the complete clinical response, safety and tolerability were good